BioSpace News Archive

XBiotech Inc. announced that it executed Manufacturing Agreement with Janssen Research & Development, LLC to manufacture clinical product, including Bermekimab, a True Human monoclonal antibody sold to Janssen by XBiotech in December 2019.

Evolus, Inc., a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced that members of its management team will be participating in the Virtual 11th Annual SVB Leerink Global Healthcare Conference.

Galapagos NV will present data at the European Crohn’s and Colitis Organization annual congress taking place 16-19 February 2022.

Vericel Corporation announced that it has entered into a long-term lease agreement for a new state-of-the-art advanced cell therapy manufacturing and corporate headquarters facility at the Network Drive campus at Northwest Park in Burlington, Massachusetts.

Adaptive Biotechnologies Corporation announced it will be participating in the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.

Wave Life Sciences Ltd., a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced two publications in the journal Nucleic Acids Research supporting the incorporation of PN backbone chemistry modifications in stereopure oligonucleotides as a significant advancement for the therapeutic oligonucleotide field.

4D Molecular Therapeutics announced updated interim clinical data from the on-going 4D-310 Phase 1/2 trial in patients with Fabry disease will be presented at the upcoming 18th Annual WORLDSymposium that will take place in San Diego, CA and virtually from February 7-11, 2022.

NeuroOne Medical Technologies Corporation announces today it will host a conference call to discuss financial results for its first quarter of fiscal 2022, ended December 31, 2021, on February 14, 2022 at 4:30 PM Eastern Time.

Immunic, Inc. announced that the company received a Notice of Allowance from the U.S. Patent and Trademark Office for patent application 16/644581, entitled, “IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation”.

City of Hope has completed its previously announced acquisition of Cancer Treatment Centers of America (CTCA).